Articles by Andreas Weiler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Andreas Weiler

Western CMOs Rise Again, Face New Challenges

Pharmaceutical CMOs are back on the rise, but must understand market changes and the influence of global workforce costs.
Apr 1, 2014

Increased competition from CMOs in Asia means that Western CMOs need to understand fundamental changes in the market.

A New Dawn for Western CMOs

Pharmaceutical CMOs are back on the rise, but must understand market changes and the influence of global workforce costs.
Feb 1, 2014

Increased competition from CMOs in Asia means that Western CMOs need to understand fundamental changes in the market.

Continuous Processing: Is The Pharma Industry Finally Coming Round To The Idea?

Sep 1, 2010

Industry experts discuss the merits of continuous processing technology and explain why pharma manufacturers should realize the benefits these technologies offer.

Using Microreactors in Chemical Synthesis: Batch Process versus Continuous Flow

The authors discuss the advantages of microreactors and flow chemistry for various reaction types in achieving improved process economics and reaction efficiency.
Sep 1, 2009

The authors discuss the advantages of microreactors and flow chemistry for various reaction types in achieving improved process economics and reaction efficiency.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here